Novartis Heart Drug Lowered a Genetic Risk Factor but Did Not Cut Heart Attacks or Strokes

Novartis says pelacarsen missed its main goal in an 8,323-patient late-stage trial, lowering Lp(a) without reducing cardiovascular events.

Have A Referral?